T he addition of clopidogrel to aspirin prevents ischemic complications in patients undergoing percutaneous coronary intervention (PCI) and reduces major adverse cardiovascular events in patients with non-ST-segment elevation early coronary syndromes. [1] [2] [3] More recent clinical trials 4 -6 have also shown that the addition of early clopidogrel to aspirin in ST-segment elevation myocardial infarction (STEMI) patients treated with fibrinolysis and in patients not treated with reperfusion therapy provides incremental benefit. Based on these data, the American College of Cardiology (ACC)/American Heart Association (AHA) STEMI guidelines were updated in 2007 to give a class I indication for clopidogrel administration in addition to aspirin in all STEMI patients regardless of whether they undergo reperfusion therapy (primary PCI or fibrinolysis).
In addition, the guidelines suggested that a loading dose (300 mg) of clopidogrel can be administered in patients Ͻ75 years who receive fibrinolysis or no reperfusion therapy, with no evidence for a loading dose in those Ն75 years.
By using the National Cardiovascular Data Registry Early Coronary Treatment and Intervention Outcomes Network Registry (ACTION Registry)-Get With the Guidelines (GWTG) database, we sought to describe current uptake of guideline recommendations on use of clopidogrel and trends in its use among STEMI patients according to reperfusion strategy. We also investigated the use of loading dose overall and by age and the association between clopidogrel use and in-hospital outcomes by reperfusion strategy and age group.
WHAT IS KNOWN
• Recent clinical trials have shown that the addition of early clopidogrel to aspirin in STEMI patients treated with fibrinolysis and in patients not treated with reperfusion therapy provides incremental benefit.
• The ACC/AHA STEMI guidelines were updated in 2007 to give a class I indication for clopidogrel administration in addition to aspirin in all STEMI patients regardless of whether they undergo reperfusion therapy (primary PCI or fibrinolysis).
WHAT THE STUDY ADDS
• We describe current uptake of guideline recommendations on use of clopidogrel and trends in its use among STEMI patients according to reperfusion strategy. We also investigate the use of loading dose overall and by age and the association between clopidogrel use and in-hospital outcomes by reperfusion strategy and age group.
• Use of early clopidogrel in STEMI patients selected for fibrinolysis or no reperfusion is low despite guideline recommendations. In addition, despite a lack of efficacy and safety data in elderly patients, a loading dose of clopidogrel is used in more than two thirds of elderly patients receiving fibrinolysis or no reperfusion, which may increase the risk of bleeding.
• These results demonstrate the challenges associated with the translation of evidence from clinical trials into routine practice and suggest that efforts in performance improvement around early clopidogrel use are needed.
Methods

Study Setting
The ACTION Registry-GWTG database includes early myocardial infarction patients who arrive to participating US hospitals with ischemic symptoms within 24 hours from symptom onset. This voluntary observational registry includes 383 hospitals nationwide. The main purpose of the ACTION Registry-GWTG is to document clinically relevant quality indicators in the treatment of patients with early myocardial infarction (STEMI and non-STEMI) in an effort to promote quality improvement nationally.
All hospitals obtain permission from their institutional review board to participate. Data are collected anonymously during the initial hospitalization, and because no patient identifiers are collected, individual informed consent is not required. Variables collected include timing of hospital admission, demographic and clinical information, laboratory results, use and timing of medical therapies and associated contraindications, use and timing of cardiac procedures, in-hospital outcomes, and discharge interventions and recommendations. The National Cardiovascular Data Registry has a data quality program in place to ensure that consistent and reliable data are being submitted and recorded. To maximize the completeness and accuracy of all records submitted, quality assurance measures, such as data quality reports and random site audits by trained nurse abstractors, are used. 7 
Study Population
The study population for this analysis focused on STEMI patients entered in the ACTION Registry-GWTG database by 373 US 
Reperfusion Strategies, Clopidogrel Use, and Bleeding Definitions
On the ACTION data collection form, information on PCI is collected as follows: PCI (yes or no); if yes, the site has 3 options (1, immediate primary PCI; 2, rescue PCI; or 3, stable successful reperfusion for STEMI or complete infarction after STEMI). For this analysis, the "primary PCI" group included those patients for whom primary PCI was checked as the reperfusion indication; the "fibrinolytic and/or rescue" group included patients who either received lytic therapy or PCI and for whom the rescue PCI indication was checked. The "no reperfusion" group included patients not eligible to undergo immediate reperfusion.
Early clopidogrel use was defined as clopidogrel given as follows: (1) within the first 24 hours from admission for patients undergoing primary PCI, (2) within the first 24 hours from admission for patients treated with fibrinolytics and/or rescue PCI and up to 1 hour before in-hospital PCI if performed for nonemergent and nonreperfusion purposes, and (3) within the first 24 hours from admission for patients in the no reperfusion group and up to 1 hour before in-hospital PCI if performed for nonemergent and nonreperfusion purposes. The 24-hour window was calculated as the interval from hospital admission to the time of clopidogrel administration. The clopidogrel loading dose was defined as an initial dose Ն300 mg. Major bleeding was defined as an absolute hemoglobin decrease of Ն4 g/dL (baseline-nadir hemoglobin Ն4 g/dL), intracranial hemorrhage, retroperitoneal witnessed bleed, or any red blood cell transfusion if baseline hemoglobin Ն9 g/dL or if also having a witnessed bleeding event and any red blood cell transfusion if baseline hemoglobin Ͻ9 g/dL. Bleeding in coronary artery bypass grafting patients was included as a bleed only if it occurred before surgery. Bleeding during or after surgery was not considered a bleeding event.
Statistical Analysis
Patients were categorized according to reperfusion strategy at hospital admission. Clopidogrel use within 24 hours of hospital arrival was described within each reperfusion stratum. Baseline characteristics, hospital presentation, medical treatments, and in-hospital outcomes are shown for the overall analysis population categorized by reperfusion strategy and clopidogrel use. Continuous variables are reported as medians (25th-75th percentile), and categorical variables are reported as frequencies. The Wilcoxon 2-sample test was used to compare continuous variables between patients receiving clopidogrel and those not receiving clopidogrel within each reperfusion strategy group; categorical variables were compared using 2 tests. To explore the relationship between in-hospital outcomes and early clopidogrel use by reperfusion strategy and age group, the logistic generalized estimating equations method, with exchangeable working correlation matrix, was used to account for correlations among clustered responses because patients within a hospital were more likely to be similar (eg, within-hospital correlations). 8 The covariates (baseline serum creatinine, age, systolic blood pressure on presentation, baseline troponin ratio [times the upper limit of normal], heart failure [HF only on admission, shock only, or HF with shock on admission versus none], heart rate on presentation, and prior peripheral artery disease) used for in-hospital mortality adjustment were from the validated ACTION in-hospital mortality model. The covariates (heart rate on presentation, baseline hemoglobin, baseline serum creatinine, HF [HF only on admission, shock only, or HF with shock on admission versus none], diabetes, age, female sex, prior peripheral artery disease, systolic blood pressure on presentation, weight, and home warfarin use) used for the major bleeding adjustment were from the validated ACTION in-hospital major bleeding model. 9 -11 From the original models, electrocardiographic findings (STEMI, ST-segment changes versus no ST-segment changes) were not included because our population consisted of STEMI patients. All odds ratios were reported with "no clopidogrel" as the reference group. Last, P values for the trends across time (quarter) were obtained by modeling time as an ordinal independent variable with respect to either early clopidogrel or a loading dose among reperfusion strategy.
Finally, within each reperfusion group, the use of clopidogrel is described by age group (Ͻ75 versus Ն75 years). All comparisons were 2 tailed, and PϽ0.05 was considered statistically significant. No adjustments were made for multiple comparisons because descriptive analyses were exploratory. All analyses were performed by using SAS software, version 9.2 (SAS Institute; Cary, NC).
Results
Clopidogrel Use by Reperfusion Strategy
Of the 52 140 patients included in the analysis, 37 108 (71.2%) underwent primary PCI, 5805 (11.1%) received fibrinolysis as the initial reperfusion strategy, and 9227 (17.7%) received no reperfusion. Early clopidogrel was administered to 35 848 (96.6%) of primary PCI patients but only to 1037 (17.9%) of fibrinolysis patients and 592 (6.4%) of no reperfusion patients. Among those who received clopidogrel, a loading dose was administered to 90.7% of primary PCI patients, 82.7% of fibrinolysis patients, and 74.3% of no reperfusion patients. A positive time trend in clopidogrel use was observed in fibrinolytic-treated patients during the analysis period and particularly between the last quarter of 2007 and the first quarter of 2008. No time trend change in clopidogrel use was observed among the no reperfusion patients (Figure) . The use of a loading dose increased in both fibrinolytic-treated patients and no reperfusion patients.
Clopidogrel by Age (<75 or >75 Years)
Of the 52 140 patients admitted with STEMI, 9743 (18.7%) were aged Ն75 years. Of these older patients, 5958 (61.2%) underwent primary PCI, 719 (7.4%) received fibrinolysis, and 3066 (31.5%) received no reperfusion. Early clopidogrel was given to 5704 (95.7%) of primary PCI patients aged Ն75 years, 111 (15.4%) of fibrinolysis patients aged Ն75 years, and 153 (5.0%) of no reperfusion patients aged Ն75 years. The use of early clopidogrel was slightly higher in the younger age group (Ͻ75 years) across all reperfusion strategies. The administration of a clopidogrel loading dose was also higher in younger patients, but a loading dose was used in most older patients as well (Table 1) . Table 2 shows baseline characteristics, medical treatments, and in-hospital procedures by clopidogrel use across reperfusion strategies. Overall, those who received clopidogrel were younger, less likely to present with symptoms of HF or shock, less likely to undergo a coronary artery bypass graft procedure, and less likely to be admitted to a nonacademic hospital. Among the no reperfusion patients, those who did not receive clopidogrel were more likely to be women and to have had prior HF and were less likely to receive other recommended treatments. Among all reperfusion strategies, more than two thirds of the patients who did not receive early clopidogrel were discharged with clopidogrel.
Baseline Characteristics and In-Hospital Medical Treatment
Clinical Outcomes by Clopidogrel Use
Major bleeding occurred more frequently in the older patients treated with clopidogrel across all reperfusion strategies. For patients aged Ն75 years, unadjusted bleeding rates were higher in the no reperfusion group among those receiving clopidogrel compared with no clopidogrel treatment. Even after adjustment, significantly higher odds of major bleeding with clopidogrel remained among older patients in the no reperfusion group (Table 3) . Rates of in-hospital death were 3 to 8 times lower among those who received early clopidogrel across reperfusion strategies, with the greatest difference seen in the primary PCI group. After adjustment, use of clopidogrel remained associated with a significantly lower risk of in-hospital death across all reperfusion strategies and within each age category.
Discussion
Despite evidence of benefit from clinical trials and guideline recommendations, we found that early clopidogrel is underused in most patients who receive fibrinolytics or no reperfusion for STEMI. There is high use of loading doses across reperfusion strategies in younger patients and in those Ն75 years. Early clopidogrel use did not significantly increase major bleeding, suggesting its application in practice is safe overall. Only elderly persons in the no reperfusion group had an increased risk of bleeding with clopidogrel use when compared with no clopidogrel use. This may be partly due to the use of loading doses in those at greatest risk for bleeding. These results demonstrate a continued need to optimize early use of oral antiplatelet therapy in STEMI patients. The use of clopidogrel is widely accepted in patients undergoing PCI, regardless of the indication for the procedure. 12, 13 This includes STEMI patients undergoing primary PCI, as our analysis confirms. Yet, recent clinical trials have extended the benefit of clopidogrel, in addition to aspirin, to STEMI patients not undergoing primary PCI. The Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction trial included STEMI patients aged Ͻ75 years receiving fibrinolytic therapy randomized to either clopidogrel (300-mg loading dose, followed by 75 mg/d) or placebo. 5 A loading dose of clopidogrel was given only to patients Ͻ75 years. The use of clopidogrel reduced the composite of occluded infarct-related artery, death, or recurrent MI, without increasing major bleeding and intracranial hemorrhaging. The Clopidogrel and Metoprolol in Myocardial Infarction Trial was a randomized, double-blind, placebo-controlled trial testing clopidogrel, 75 mg/d (ie, with no loading dose), in addition to aspirin in Ͼ44 000 patients with suspected early myocardial infarction not undergoing primary PCI (Ͼ90% of the patients had persistent ST elevation). Approximately half of the patients received fibrinolysis; the remaining patients received no reperfusion therapy.
Treatment with clopidogrel produced a significant reduction of the composite of death, reinfarction, and stroke and of death alone. 6 Based on these data, the 2007 focused update of the ACC/AHA guidelines for STEMI patients recommended the addition of clopidogrel to aspirin in patients treated with fibrinolysis and in those who do not receive reperfusion (class I). The guidelines also state that the efficacy and safety of a loading dose in elderly patients are unknown. 14 Our findings show that early clopidogrel is infrequently given to patients who receive fibrinolytics or no reperfusion. Although a positive trend in clopidogrel use was observed in the fibrinolytic group, the increase was modest (from an average 15-20%) soon after the ACC/AHA STEMI guideline publication and did not increase further over time. No change occurred over time in the use of clopidogrel among the no reperfusion patients. We could not identify any clinical feature that was associated with clopidogrel use in those groups, suggesting unmeasured factors were at play. The coronary artery bypass graft procedures were more frequent in the no clopidogrel group, which may explain, in part, the withholding of clopidogrel treatment in this group.
Among those who did receive clopidogrel, we noted a significant increase in the use of a loading dose in both fibrinolytic and no reperfusion groups. Interestingly, a loading dose of clopidogrel is often given even to elderly persons, for whom safety is unproved. These data are likely the first to provide some safety information in an elderly population. Somewhat reassuringly, we found that elderly patients in the fibrinolytic group receiving clopidogrel did not experience a higher rate of bleeding. Only elderly patients in the no reperfusion group, who received clopidogrel, had a significantly higher risk of bleeding.
In-hospital mortality was significantly higher among patients who did not receive clopidogrel, particularly in the primary PCI group. The effect of clopidogrel on mortality was also consistent within each age subgroup, although the number of events was small in the no reperfusion and fibrinolytic groups. This difference in death rate cannot be explained solely by clopidogrel use, and potential confounding exists. Also, patients not receiving clopidogrel had other recommended therapies withheld, such as ␤-blockers, platelet glycoprotein IIb/IIIa inhibitors, and statins; these therapies are known to be associated with reduced mortality in patients with early myocardial infarction. We can speculate that a higher risk profile at baseline may have led the physicians to withhold clopidogrel and that the higher risk profile may be the main driver of worse outcomes. The presence of other factors (clopidogrel intolerance, intubation, and active bleeding) may present challenges for the application of clopidogrel broadly.
We can speculate on several explanations regarding our findings. First, there is a natural lag between the publication of practice guidelines and their adoption in clinical practice. The time of data collection used in this article was relatively close to when the guidelines were published. Because the goal of the ACC/AHA's issuance of a focused updated is to quickly translate recent research findings into clinical practice without waiting for the publication of a fully revised guideline document, these findings should reinforce the need The reference group was the no clopidogrel use group. The n values are in-hospital outcomes. OR indicates odds ratio. *Excluded transferred-out patients. †Variables in the ACTION in-hospital major bleeding model are as follows: heart rate on presentation, baseline hemoglobin, baseline serum creatinine, HF (HF only on admission, shock only, or HF with shock on admission vs none), diabetes, age, female sex, prior peripheral artery disease, systolic blood pressure on presentation, weight, and home warfarin.
‡Variables in the ACTION in-hospital mortality model are as follows: baseline serum creatinine, age, systolic blood pressure on presentation, baseline troponin ratio (times the upper limit of normal), HF (HF only on admission, shock only, or HF with shock on admission vs none), heart rate on presentation, and prior peripheral artery disease.
for educational efforts to expedite the application of clinical trial results in practice. Slow implementation is not the only possible factor causing low use of clopidogrel in medically managed STEMI patients. Another potential factor is the continued lack of awareness of the benefits of clopidogrel outside of the PCI setting. Also, low use of clopidogrel has been described in patients with non-ST-segment elevation early coronary syndromes not treated with PCI, despite available evidence. 15 Critical pathway tool kits have been implemented to assist with use and dosing of medications in the setting of STEMI. 16 Finally, despite the guideline recommendations, US physicians may question the applicability of these recent trial results to practice because the Clopidogrel and Metoprolol in Myocardial Infarction Trial was conducted only in China and the Clopidogrel as Adjunctive Reperfusion Therapy trial was conducted primarily outside of the United States. In addition, the primary results of the Clopidogrel as Adjunctive Reperfusion Therapy trial showed that clopidogrel had the greatest effect on the rate of an occluded infarct-related artery (41% reduction in the odds) rather than a clear reduction in each hard clinical end point, such as death or myocardial infarction. 17 Some considerations need to be considered when interpreting these data. First, because data are collected retrospectively, there may have been several factors leading to the administration or withholding of clopidogrel that we were unable to capture and account for. Second, hospitals participating in ACTION may not be representative of all US hospitals because participation is voluntary, and our results could overestimate clopidogrel use because hospitals that agreed to participate are likely to be more interested in adherence to guideline recommendations. Third, although bleeding and mortality risk-adjustment models have been recently derived and validated in the ACTION Registry-GWTG, it is possible that some residual confounding still exists. Fourth, because these 2 models are developed for the overall population (STEMI and non-STEMI) and not among primary or lytic patients, door-to-balloon time and door-to-drug time were not included. However, a sensitivity analysis including these 2 additional variables yielded similar results after adjusting for door-to-balloon time among primary PCI and door-toneedle time among lytic patients. Finally, only in-hospital outcomes are collected in the registry, so longer-term outcomes could not be assessed.
Conclusions
The use of early clopidogrel in STEMI patients selected for fibrinolysis or no reperfusion is low despite guideline recommendations. In addition, despite a lack of efficacy and safety data in elderly patients, a loading dose of clopidogrel is used in more than two thirds of elderly patients receiving fibrinolysis or no reperfusion, which may increase the risk of bleeding. These results demonstrate the challenges associated with the translation of evidence from clinical trials into routine practice and suggest that efforts in performance improvement around early clopidogrel use are needed.
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